Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Efficacy of Nirsevimab in Neonates, Infants, and Children Vulnerable to RSV
NCT07109297Phase 4Active, not recruiting
- Sponsor
- Sanofi
- Start
- Jul 2025
- Primary completion
- Jun 2026
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of nirsevimab in respiratory syncytial virus infection (RSV), sponsored by Sanofi. Primary endpoints: Presence of immediate adverse events at 30 minutes, Presence of non-serious adverse events at 1 month and 3 more. Started Jul 2025; status: active, not recruiting.
02
Drugs
nirsevimab
03
Conditions
respiratory syncytial virus infection (RSV)
Beyond the preview
Go deeper on NCT07109297.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07109297.